Urea Cycle Disorder (UCD) Market Research Report forecast 2019-2023
Summary - A new market study, titled “Urea Cycle Disorder
(UCD) Market: Industry Analysis & Outlook (2019-2023)” has been featured on
Wise Guy Reports.
Urea cycle disorders (UCDs)
are a group of orphan inherited defects of six enzymes and two transporters
that constitute the urea cycle in the periportal liver cells. The age of onset
symptoms vary between the different types of UCDs. UCDs often occurs during the
period of infancy due to triggered postnatal catabolism.
The diagnosis is made by analysis of the urine and blood for
abnormal metabolites (substance produced by metabolism), and high ammonia
levels. Frequent blood tests are done to monitor ammonia levels. The treatment
of urea cycle disorders consists of dietary management to limit ammonia
production. A liver transplant can be an effective treatment for urea cycle
disorder for the proper functioning of urea cycle.
The urea cycle disorder treatment market in the U.S. and
Europe is expected to grow rapidly in the next few years. Several
pharmaceutical companies are under the development process of their late stage
pipeline drugs for urea cycle disorders. Factors such as, increasing healthcare
expenditures in the U.S, rise in the U.S. pharmaceutical R&D expenditures
and collaboration between pharmaceutical companies and research institutes have
driven the growth of the U.S. urea cycle disorder treatment market. Further,
upcoming launches of anti-UCD drugs would contribute to the expansion of the
urea cycle disorder treatment market in the U.S. as well as in Europe.
The U.S. urea cycle disorder treatment market is dominated
by certain key players including Horizon Pharma Inc., Ultragenyx
Pharmaceuticals Inc., Aeglea Bio Therapeutics and Synlogix. Among all the key
players, Horizon Pharma ruled the U.S. UCD treatment market owing to the strong
performance of its product. Horizon’ Ravicti is the market leader due its
strong curative impact on the patients with UCD. The remaining key players have
their products under the development process of pipeline drugs for UCDs. There
would be a generic competition between the upcoming anti-UCD drugs in the
coming years.
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4111974-urea-cycle-disorder-ucd-market-industry-analysis-outlook-2019-2023
About
Us :
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and
governments around the globe.
Contact
Us:
NORAH
TRENT
Ph: +162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment